RecruitingPhase 2NCT07369024

Sub-dissociative Dose Ketamine in Treatment of Vaso-occlusive Pain Event in Children and Young Adults

Sub-dissociative Dose Ketamine in Treatment of Vaso-occlusive Pain Event in Children and Young Adults: A Randomized Control Trial

Sponsor

Mohsen Saidinejad

Enrollment

120 participants

Start Date

Apr 1, 2026

Study Type

INTERVENTIONAL

Conditions

Pain Management Sickle Cell Disease Vaso-Occlusive Crises Vaso-Occlusive Pain Episode in Sickle Cell Disease Ketamine Infusion

Summary

The purpose of this research is to see if ketamine is effective and safe in treating children and young adults with sickle cell disease experiencing sickle cell related pain. In this study, we will compare the outcomes (such as pain scores) in persons who receive standard of care pain medicine (an opioid such as morphine) plus a low dose (amount) of ketamine to those who receive only standard of care pain medicine.

Eligibility

Min Age: 5 YearsMax Age: 20 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a drug called Normal Saline Placebo Infusion and a drug called Sub-dissociative Ketamine Infusion for people with ketamine infusion, pain management, and other related conditions. The study is currently recruiting participants at 1 location. People eligible for this study include aged 5 Years to 20 Years.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGSub-dissociative Ketamine Infusion

0.25 mg/kg of IV ketamine within a 20-minute infusion of 100 milliliters of normal saline (NS)

DRUGNormal Saline Placebo Infusion

20-minute infusion of 100 milliliters of normal saline

Locations(1)

Harbor UCLA Medical Center

Torrance, California, United States

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT07369024

Related Trials

A Study to Investigate the Efficacy and Safety of Crizanlizumab (5 mg/kg) Compared With Placebo in Adolescent and Adult Sickle Cell Disease Patients Who Experience Frequent Vaso-Occlusive Crises (SPARKLE)

NCT0643908232 locations

A Phase I/II Study of ITU512 in Healthy Participants and Patients With Sickle Cell Disease

NCT065466709 locations